A detailed history of Allworth Financial LP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Allworth Financial LP holds 4 shares of BPMC stock, worth $361. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4
Previous 4 -0.0%
Holding current value
$361
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 24, 2024

BUY
$43.96 - $92.84 $87 - $185
2 Added 100.0%
4 $0
Q3 2023

Oct 31, 2023

SELL
$46.9 - $66.0 $281 - $396
-6 Reduced 75.0%
2 $0
Q2 2023

Jul 18, 2023

BUY
$42.2 - $66.37 $337 - $530
8 New
8 $0
Q3 2022

Oct 18, 2022

BUY
$49.93 - $77.7 $9,636 - $14,996
193 New
193 $13,000
Q2 2022

Jul 13, 2022

SELL
$45.23 - $70.15 $180 - $280
-4 Closed
0 $0
Q1 2022

Apr 22, 2022

BUY
$54.1 - $110.08 $216 - $440
4 New
4 $0
Q1 2020

Apr 17, 2020

SELL
$48.11 - $82.22 $16,405 - $28,037
-341 Closed
0 $0
Q4 2019

Jan 16, 2020

BUY
$66.73 - $82.59 $22,754 - $28,163
341 New
341 $27,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.